Atomwise’s Post

Atomwise is revolutionizing how drugs are discovered using #AI. Our deep learning technology for structure-based drug discovery enables our pipeline of small-molecule drug candidates.  Learn more about Atomwise and how we’re changing traditional #drugdiscovery ⬇️

Promising news for cancer research! A team from the University of Pavia, Italy, leveraged AtomNet #AI to design small molecules targeting Voltage-dependent Anion-selective Channel 1 (VDAC1), a protein implicated in various cancers. Their approach focused on immobilizing a flexible helix within VDAC1, thereby modifying a metabolite binding site and a putative protein-protein interaction (PPI) implicated in tumor cell proliferation. These VDAC1 molecular glues demonstrated dose-dependent efficacy in reducing cancer cell viability while exhibiting minimal impact on healthy cells and organoids. The research lays a foundation for future development of these molecules as potential cancer therapeutics. Read more here: https://lnkd.in/e3wp5kHd

The verdict is in! Our proprietary AtomNet #AI platform is a viable alternative to high-throughput screening for discovering structurally novel chemical matter, regardless of the target: https://lnkd.in/ebPpWhnH In the largest, most comprehensive virtual high-throughput screening campaign of its kind, we applied AtomNet to 318 targets covering a wide range of classes. AtomNet found hits for 235 targets, averaging over seven structurally distinct bioactive compounds per target. Even more impressively, most of the targets assessed lacked any target-specific training data, with hits representing first-in-class binders to the target. Check out our publication in Nature Scientific Reports for more details: https://lnkd.in/eFcNAC3S We believe that AtomNet's ability to find novel chemical matter even for data-poor targets is a significant achievement in the field of AI #DrugDiscovery. We are grateful to our 600+ talented collaborators who contributed to this effort!

https://lnkd.in/gW7MEN8K

We're excited to announce the nomination of our very first AI-driven development candidate, focused on TYK2 inhibition. This marks a significant milestone in our journey to revolutionize drug discovery and development through artificial intelligence. Joining us on this incredible venture is Dr. Neely Mozaffarian, MD, PhD, who has been appointed as our new Chief Medical Officer. With her expertise and leadership, we're poised to advance groundbreaking solutions that could transform the lives of millions. At Atomwise, we're committed to using AI to accelerate drug discovery and improve patient outcomes. This appointment and our strategy are a testament to our dedication to creating #FirstInClass and #BestInClass medicines for patients. Stay tuned for more updates as we continue to push the boundaries of what's possible in medicine and science! #AI #DrugDiscovery #HealthcareInnovation #TYK2Inhibition #Atomwise https://lnkd.in/ecSizR_6

We're excited to announce the nomination of our very first AI-driven development candidate, focused on TYK2 inhibition. This marks a significant milestone in our journey to revolutionize drug discovery and development through artificial intelligence. Joining us on this incredible venture is Dr. Neely Mozaffarian, MD, PhD, who has been appointed as our new Chief Medical Officer. With her expertise and leadership, we're poised to advance groundbreaking solutions that could transform the lives of millions. At Atomwise, we're committed to using AI to accelerate drug discovery and improve patient outcomes. This appointment and our strategy are a testament to our dedication to creating #FirstInClass and #BestInClass medicines for patients. Stay tuned for more updates as we continue to push the boundaries of what's possible in medicine and science! #AI #DrugDiscovery #HealthcareInnovation #TYK2Inhibition #Atomwise https://lnkd.in/ecSizR_6

Greg Friedland, Sr. Principal Software Engineer at @Atomwise will be presenting at the upcoming ACS Fall Symposium "Taking a Deep Dive into the Chemical Space” on August 16th. His presentation is titled "Complementary Methods for Exploring Ultra-large Combinatorial Synthesis Libraries in Fragment-space," work of which was done in collaboration with his fantastic co-authors Saulo de Oliveira, Aryan Pedawi, Adrian Morrison, and Henry van den Bedem, + many more esteemed colleagues at Atomwise. Make sure you catch Greg and the other speakers in this symposium as they "Deep Dive into the Chemical Space!" #AI #drugdiscovery https://hubs.la/Q01-PBG90